Hypertension |
High Blood Pressure; Hypertension/High Blood Pressure |
Clinical Trial: The Efficacy and Safety of Sildenafil Citrate Used in Combination with Intravenous Epoprostenol in PAH
This study is currently recruiting patients.
Verified by Pfizer September 2005
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Pulmonary Hypertension | Drug: Sildenafil citrate | Phase III |
MedlinePlus related topics: Pulmonary Hypertension
Study Type: Interventional
Study Design: Educational/Counseling/Training, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title: A Multinational, Multi-Center, Randomised, Double-Bind, Placebo-Controlled, Parallel Group Study to Assess the Safety and Efficacy of a Subject Optimised Dose of Sildenafil Citrate (20, 40, or 80 Mg. Sildenafil Citrate TID) Based on the Toleration, When Used in Combination with Intravenous Prostacyclin( Epoprostenol) in the Treatment of Pulmonary Arterial Hypertension.
Secondary Outcomes: Secondary Endpoints:; 1. Change from Baseline at Week 16 in mean Pulmonary Artery Pressure (mPAP).; 2. Time from randomisation to the first occurrence of clinical worsening defined as death or lung transplantation or hospitalisation due to PAH
Expected Total Enrollment: 265
Study start: October 2002
Eligibility
Inclusion Criteria:
- Patients with pulmonary arterial hypertension caused by primary PAH, associated with connective tissue disease or following surgical repair of a congenital heart lesion
Exclusion Criteria:
- PH other than PAH
Location and Contact Information
California
Pfizer Investigational Site, Torrance, California, 90502, United States; Recruiting
Pfizer Investigational Site, Torrance, California, 90509, United States; Recruiting
Pfizer Investigational Site, Torrence, California, 90502, United States; Recruiting
Pfizer Investigational Site, La Jolla, California, 92037, United States; Recruiting
Pfizer Investigational Site, San Diego, California, 92103, United States; Recruiting
Pfizer Investigational Site, Los Angeles, California, 90033, United States; Recruiting
Colorado
Pfizer Investigational Site, Denver, Colorado, 80262, United States; Recruiting
Illinois
Pfizer Investigational Site, Chicago, Illinois, 60637, United States; Recruiting
Kansas
Pfizer Investigational Site, Kansas City, Kansas, 66160, United States; Recruiting
Louisiana
Pfizer Investigational Site, New Orleans, Louisiana, 70112, United States; Completed
Maryland
Pfizer Investigational Site, Baltimore, Maryland, 21205, United States; Recruiting
Massachusetts
Pfizer Investigational Site, Boston, Massachusetts, 02114, United States; Recruiting
Pfizer Investigational Site, Boston, Massachusetts, 02111, United States; Recruiting
Michigan
Pfizer Investigational Site, Ann Arbor, Michigan, 48109, United States; Recruiting
Minnesota
Pfizer Investigational Site, Rochester, Minnesota, 55905, United States; Recruiting
Pfizer Investigational Site, Minneapolis, Minnesota, 55407, United States; No longer recruiting
Missouri
Pfizer Investigational Site, St. Louis, Missouri, 63110, United States; Recruiting
Nebraska
Pfizer Investigational Site, Omaha, Nebraska, 68105, United States; Recruiting
Pfizer Investigational Site, Omaha, Nebraska, 68198-2125, United States; Recruiting
New York
Pfizer Investigational Site, New York, New York, 10032, United States; Recruiting
North Carolina
Pfizer Investigational Site, Durham, North Carolina, 27710, United States; Recruiting
Ohio
Pfizer Investigational Site, Cleveland, Ohio, 44195, United States; Recruiting
Pfizer Investigational Site, Cincinnati, Ohio, 45219, United States; Recruiting
Pfizer Investigational Site, Cincinnati, Ohio, 45219, United States; Recruiting
Pfizer Investigational Site, Cincinnati, Ohio, 45267-0769, United States; Recruiting
Pennsylvania
Pfizer Investigational Site, Pittsburgh, Pennsylvania, 15213, United States; Recruiting
Rhode Island
Pfizer Investigational Site, Providence, Rhode Island, 02903, United States; Recruiting
Tennessee
Pfizer Investigational Site, Nashville, Tennessee, 37232, United States; Recruiting
Pfizer Investigational Site, Nashville, Tennessee, 37232-5735, United States; Recruiting
Texas
Pfizer Investigational Site, Houston, Texas, 77030, United States; Recruiting
Utah
Pfizer Investigational Site, Salt Lake City, Utah, 84143, United States; Recruiting
Wisconsin
Pfizer Investigational Site, Milwaukee, Wisconsin, 53215, United States; Recruiting
Pfizer Investigational Site, Milwaukee, Wisconsin, 53277, United States; Recruiting
Pfizer Investigational Site, Milwaukee, Wisconsin, 53226, United States; Recruiting
Belgium
Pfizer Investigational Site, Leuven, 3000, Belgium; Recruiting
Canada, Alberta
Pfizer Investigational Site, Edmonton, Alberta, T6G 2B7, Canada; Recruiting
Canada, British Columbia
Pfizer Investigational Site, Vancouver, British Columbia, V5Z-3J5, Canada; No longer recruiting
Canada, Ontario
Pfizer Investigational Site, Toronto, Ontario, M5G 2C4, Canada; Recruiting
Pfizer Investigational Site, London, Ontario, N6A 4G5, Canada; No longer recruiting
Pfizer Investigational Site, Ottawa, Ontario, K1Y 4E9, Canada; Recruiting
Pfizer Investigational Site, Ottawa, Ontario, K1Y 4W7, Canada; Recruiting
Canada, Quebec
Pfizer Investigational Site, Montreal, Quebec, H3T 1E2, Canada; Recruiting
Czech Republic
Pfizer Investigational Site, PRAGUE 2, 128 08, Czech Republic; Recruiting
Denmark
Pfizer Investigational Site, Kobenhavn, 2100, Denmark; Recruiting
France
Pfizer Investigational Site, Strasbourg Cedex 02, 67098, France; Recruiting
Pfizer Investigational Site, Grenoble Cedex 09, 38043, France; Recruiting
Pfizer Investigational Site, Clamart Cedex, 92141, France; Recruiting
Israel
Pfizer Investigational Site, Petach Tikva, 49100, Israel; Recruiting
Italy
Pfizer Investigational Site, Bologna, 40138, Italy; Recruiting
Netherlands
Pfizer Investigational Site, Amsterdam, 1081 HV, Netherlands; Recruiting
Pfizer Investigational Site, Nieuwegein, 3435CM, Netherlands; Recruiting
Spain
Pfizer Investigational Site, Barcelona, 08036, Spain; Recruiting
Pfizer Investigational Site, Madrid, 28041, Spain; Recruiting
United Kingdom
Pfizer Investigational Site, Glasgow, G11 6NT, United Kingdom; Recruiting
United Kingdom, Cambridgeshire
Pfizer Investigational Site, Papworth Everard, Cambridgeshire, CB3 8RE, United Kingdom; Recruiting
Pfizer CT.gov Call Center, Study Director, Pfizer
More Information
Last Updated: September 11, 2005
Record first received: September 8, 2005
ClinicalTrials.gov Identifier: NCT00159861
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- 'White Coat Hypertension' Common Among Sleep Apnea Patients (American College of Chest Physicians)
- About High Blood Pressure: A Special Message for Women (American Heart Association)

Not Signed In -

